Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia.

John C Byrd1, Stephan Stilgenbauer, Ian W Flinn

  • 1The Ohio State University, Columbus, OH 43210, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

HemaSphere·2026
Same author

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal of hematology & oncology·2026
Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026
Same author

Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.

American journal of cancer research·2025
Same author

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Blood advances·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Chronic lymphocytic leukemia (CLL) treatment has advanced with new therapies and risk stratification methods. Understanding prognostic factors and targeted treatments improves outcomes for patients with refractory disease.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Chronic lymphocytic leukemia (CLL) was historically viewed as a uniform disease with limited treatment options.
  • Recent advances have identified key prognostic factors, including V(H) mutational status, ZAP-70, p53 function, and chromosomal aberrations.
  • These factors enable better risk stratification and prediction of disease progression and survival.

Purpose of the Study:

  • To provide a comprehensive overview of chronic lymphocytic leukemia (CLL) natural history and management.
  • To discuss risk stratification strategies based on molecular and genomic factors.
  • To review current and emerging therapeutic options for CLL patients, including those with refractory disease.

Main Methods:

  • Review of diagnostic criteria and prognostic factors for CLL.

Related Experiment Videos

  • Analysis of molecular and genomic aberrations for risk stratification.
  • Evaluation of monotherapy and combination therapy trials, including nucleoside analogs, monoclonal antibodies, and novel targeted agents.
  • Discussion of autologous and allogeneic immunotherapy.

    • Main Results:

    • Identification of high-risk CLL patients based on specific biologic markers.
    • High complete and overall response rates achieved with combination therapies in initial treatment.
    • Challenges in managing fludarabine-refractory CLL.
    • Promising investigational therapies including new antibodies and kinase inhibitors.

    Conclusions:

    • Risk stratification in CLL has become more complex but allows for personalized treatment approaches.
    • Advances in therapy have significantly improved response rates for symptomatic and refractory CLL.
    • Ongoing research into novel targeted therapies holds promise for further improving patient outcomes.